Regulatory Information
NOVARTIS (SINGAPORE) PTE LTD
Therapeutic
Prescription Only
Formulation Information
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
SUBCUTANEOUS
Medical Information
R03DX05
omalizumab
Manufacturer Information
NOVARTIS (SINGAPORE) PTE LTD
Novartis Pharma Stein AG
Takeda Austria GmbH
DELPHARM DIJON - QUETIGNY
Active Ingredients
Documents
Package Inserts
Xolair PI.pdf
Approved: January 27, 2023